EUCTR2015-005053-12-DE进行中（未招募）1 期
A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma - Phase III trial of pembrolizumab or brentuximab vedotin in Hodgkin lymphoma
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •– =18 years of age
- •– Relapsed or refractory classical Hodgkin lymphoma
- •– Measurable disease on spiral computed tomography (CT) or combined CT/positron emission tomography (PET) scan
- •– Evaluable core or excisional lymph node biopsy
- •– Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •– Adequate organ function (laboratory studies)
- •– Negative pregnancy/lactation
- •– Adequate contraception (males and females)
- •Refer to the protocol for more detail on each inclusion criterion.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 210
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •1. Has severe (= Grade 3) hypersensitivity to the active substance or to any of the excipients in BV or pembrolizumab.
- •2. Is currently participating in or has participated in a study of an investigational agent and is currently receiving study therapy or has participated in a study of an investigational agent and has received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •3. Has a diagnosis of immunosuppression or is receiving systemic steroid therapy (exceeding 10 mg daily of prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •4. Has had a prior monoclonal antibody within 4 weeks prior to first dose of therapy in the study or who has not recovered (i.e., =Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.
- •5. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy including investigational agents within 4 weeks prior to study Day 1 or who has not recovered (i.e., =Grade 1 or at baseline) from AEs due to a previously administered agent.
- •6. Has undergone prior allo-SCT within the last 5 years.
- •7. Has a known additional malignancy that is progressing or has required active treatment in the last 3 years.
- •8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study
- •screening), clinically stable, and without requirement of steroid treatment for at least 14 days prior to the first dose of trial treatment.
- •9. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with the use of disease modifying agents, corticosteroids, or immunosuppressive drugs).
- •10. Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
- •11. Has an active infection requiring systemic therapy.
- •12. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the trial.
- •13. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of pembrolizumab or 180 days after the last dose of BV.
- •14. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, CTLA-4 antibody (including ipilimumab), or OX-40, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- •15. Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.
- •16. Has active hepatitis B (HBV) (e.g., HBsAg reactive) or hepatitis C (HCV) (e.g., HCV RNA [qualitative] is detected).
- •17. Has received a live vaccine within 30 days prior to first dose.
- •18. Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
- •19. Is eligible for allogeneic or autologous stem cell transplantation per investigator assessment.
研究者
相似试验
进行中（未招募）
1 期
Keytruda® will be compared to Adcetris® in this study to find out how effective and safe Keytruda is in treating a cancer called Hodgkin lymphoma.Relapsed or refractory classical Hodgkin lymphomaMedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2015-005053-12-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
Keytruda® will be compared to Adcetris® in this study to find out how effective and safe Keytruda is in treating a cancer called Hodgkin lymphoma.EUCTR2015-005053-12-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
Keytruda® will be compared to Adcetris® in this study to find out how effective and safe Keytruda is in treating a cancer called Hodgkin lymphoma.Relapsed or refractory classical Hodgkin lymphomaMedDRA version: 20.0Level: LLTClassification code 10020328Term: Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2015-005053-12-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
Keytruda® will be compared to Adcetris® in this study to find out how effective and safe Keytruda is in treating a cancer called Hodgkin lymphoma.Relapsed or refractory classical Hodgkin lymphomaEUCTR2015-005053-12-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.300
进行中（未招募）
1 期
Keytruda® will be compared to Adcetris® in this study to find out how effective and safe Keytruda is in treating a cancer called Hodgkin lymphoma.EUCTR2015-005053-12-CZMerck Sharp & Dohme Corp.300